2023
AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review
Garcia-Tsao G, Abraldes J, Rich N, Wong V. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review. Gastroenterology 2023, 166: 202-210. PMID: 37978969, DOI: 10.1053/j.gastro.2023.10.016.Peer-Reviewed Original ResearchConceptsSpontaneous bacterial peritonitisAcute kidney injuryLarge-volume paracentesisEffective arterial blood volumeVasoactive drugsVariceal hemorrhageArterial blood volumeHRS-AKIUncomplicated ascitesIntravenous albuminVolume statusPractice UpdateBlood volumeChronic liver failure grade 3Best practice advice statementsClinical Practice Updates CommitteeEnd-stage liver diseaseAGA Clinical Practice UpdateForms of AKIIntensive care unit monitoringAGA Governing BoardCombination of vasoconstrictorsInitial endoscopic hemostasisPatient's volume statusClinical Practice Update
2012
The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis
Bari K, Miñano C, Shea M, Inayat IB, Hashem HJ, Gilles H, Heuman D, Garcia–Tsao G. The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis. Clinical Gastroenterology And Hepatology 2012, 10: 1169-1175. PMID: 22801062, PMCID: PMC3678262, DOI: 10.1016/j.cgh.2012.06.027.Peer-Reviewed Original ResearchConceptsPostparacentesis circulatory dysfunctionRecurrence of ascitesVasoconstrictor groupAlbumin groupRefractory ascitesAscites recurrenceCombination of midodrineCombination of octreotidePlacebo-controlled trialLarge-volume paracentesisEffective blood volumeTreatment of choiceSingle intravenous doseOral midodrinePreventing RecurrenceRenal failureCirculatory dysfunctionMedian timeSerum levelsIntravenous doseIntramuscular injectionIntravenous administrationAscitesMidodrineBlood volume
2011
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*
Boyer TD, Sanyal AJ, Garcia‐Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P, Group T. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*. Liver Transplantation 2011, 17: 1328-1332. PMID: 21837734, PMCID: PMC3760727, DOI: 10.1002/lt.22395.Peer-Reviewed Original ResearchMeSH KeywordsAlbuminsCohort StudiesHepatorenal SyndromeHumansLiver FailureLiver TransplantationLypressinPrognosisSurvival RateTerlipressinVasoconstrictor AgentsConceptsHepatorenal syndrome type 1Liver transplantationHepatorenal syndromeSyndrome type 1Nontransplant patientsTransplant patientsSurvival benefitSurvival rateType 1Pretransplant renal functionUse of terlipressinClear survival benefitCohort of patientsSurvival of patientsHRS reversalPosttransplant managementLiver transplantPosttransplant survivalMost patientsPosttransplant outcomesRenal functionPoor prognosisTerlipressinPatientsTransplantation
2008
Acute kidney injury in cirrhosis
Garcia‐Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008, 48: 2064-2077. PMID: 19003880, DOI: 10.1002/hep.22605.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAcute renal failureHepatorenal syndromeKidney injurySerum creatinineSpecific therapyEffective arterial blood volumeUseful bridging therapyAcute tubular necrosisRenal blood flowSpontaneous bacterial peritonitisArterial blood volumeBridging therapyLiver transplantationPrerenal azotemiaRenal dysfunctionRenal failureTubular necrosisBacterial peritonitisVasodilatory stateRelative hypovolemiaVolume repletionCommon causeCirrhosisBlood flowA Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome
Sanyal AJ, Boyer T, Garcia–Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P, Group T. A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome. Gastroenterology 2008, 134: 1360-1368. PMID: 18471513, PMCID: PMC3730280, DOI: 10.1053/j.gastro.2008.02.014.Peer-Reviewed Original ResearchMeSH KeywordsDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesGermanyHepatorenal SyndromeHumansInjections, IntravenousKidney Function TestsLypressinMaleMiddle AgedProspective StudiesRussiaSeverity of Illness IndexShock, SepticSurvival RateTerlipressinTreatment OutcomeUnited StatesVasoconstrictor AgentsConceptsHRS type 1Type 1 HRSSCr levelsTreatment successDay 14Type 1Total adverse event rateType 1 hepatorenal syndromePlacebo-controlled clinical trialSafety of terlipressinTrial of terlipressinAdvanced liver diseaseFunctional renal failureNonfatal myocardial infarctionSerum creatinine levelsTransplantation-free survivalAdverse event ratesSyndrome type 1Arterial vasoconstrictorHepatorenal syndromeHRS reversalCreatinine levelsRenal failureRenal functionLiver disease
1999
Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility
Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann R. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. Journal Of Clinical Investigation 1999, 104: 1223-1233. PMID: 10545521, PMCID: PMC409820, DOI: 10.1172/jci7458.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBacterial TranslocationDose-Response Relationship, DrugLiver Cirrhosis, ExperimentalLymph NodesMaleMesenteric ArteriesMethoxamineNitric OxideNitric Oxide SynthasePerfusionPressureProtein IsoformsRatsRats, Sprague-DawleyStress, MechanicalTumor Necrosis Factor-alphaVasoconstrictionVasoconstrictor AgentsConceptsMesenteric lymph nodesEndothelial NO synthaseTNF-alpha productionAscitic cirrhotic ratsBacterial translocationCirrhotic ratsMesenteric vasculatureNitric oxidePresence of BTSuperior mesenteric arterial bedMesenteric arterial bedNitro-L-arginineTNF-alpha synthesisVascular hyporesponsivenessArterial vasodilationLiver cirrhosisLymph nodesVascular contractilityVascular responsesTNF-alphaArterial bedNO inhibitorNOS activityNO overproductionNO synthase
1995
Cirrhotic ascites: pathogenesis and management.
Garcia-Tsao G. Cirrhotic ascites: pathogenesis and management. The Gastroenterologist 1995, 3: 41-54. PMID: 7743121.BooksConceptsPathogenesis of ascitesComplications of cirrhosisNegative sodium balanceAccumulation of fluidSinusoidal hypertensionLiver transplantationSalt restrictionPortosystemic shuntingPeripheral vasoconstrictorNonsurgical sideIntravascular volumeCurrent therapiesIntraperitoneal fluidSodium balanceTherapeutic priorityTherapeutic measuresPeritoneal spacePeritoneal cavitySystemic circulationAscitesEfflux of fluidPatientsDiureticsPathogenesisFuture studies